Company profile: Protembis
1.1 - Company Overview
Company description
- Provider of a catheter-based cerebral protection system (ProtEmbo) that deflects embolic material away from the cerebrovascular circulation during left-sided heart procedures, particularly transcatheter aortic valve replacement (TAVR).
Products and services
- ProtEmbo® Cerebral Protection System: A catheter-based, simple and reliable cerebral protection product that deflects embolic material away from cerebrovascular circulation during left-sided heart procedures, particularly transcatheter aortic valve replacement (TAVR)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Protembis
Gilgamesh Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel psychotropic and psychedelic-inspired medicines for depression, bipolar depression, anxiety, stress-related disorders, and other conditions, developing compounds optimized for safety, tolerability, duration, and efficacy, including GM-1020 (oral, rapid-acting, non-dissociative NMDAR antagonist for potential at-home use), GM-2505 (short-acting 5-HT2A agonist), GM-5022 (non-hallucinogenic neuroplastogen), and GM-3009 (safer ibogaine analog for opioid use disorder, PTSD, and TBI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gilgamesh Pharmaceuticals company profile →
Cara Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapeutics targeting pain and inflammation, including KORSUVA (difelikefalin), an FDA-approved treatment for moderate to severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis, and research and development focused on treating pruritus in Notalgia Paresthetica.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cara Therapeutics company profile →
Alliance
HQ: United States
Website
- Description: Provider of in-home neurodiagnostic testing services, including video EEG testing and remote EEG monitoring, as well as cardiac monitoring solutions such as mobile cardiac telemetry, extended Holter testing, and event monitoring, plus cloud-based EEG software for secure access to EEG data and synchronized review of EEG and video recordings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alliance company profile →
AskBio
HQ: United States
Website
- Description: Provider of AAV-based gene therapies for genetic disorders and rare diseases, offering proprietary AAV technology, manufacturing capabilities, and in-house clinical programs. Pipeline includes AB-1002 for advanced heart failure (GenePHIT Phase 2), ACT-101 for late-onset Pompe disease, and NAN-101 for congestive heart failure, plus research on AAV immune responses and episome configuration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AskBio company profile →
Synchroneuron
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies under development for tardive dyskinesia and other related movement disorders, including lead candidate SNC-102, a sustained-release formulation of acamprosate calcium in phase 2 trials for tardive dyskinesia and Tourette syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synchroneuron company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Protembis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Protembis
2.2 - Growth funds investing in similar companies to Protembis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Protembis
4.2 - Public trading comparable groups for Protembis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →